Ashland Inc. logo

Ashland Inc. (ASH)

Market Closed
3 Jun, 20:00
NYSE NYSE
$
57. 00
-0.58
-1.01%
$
2.62B Market Cap
25.2 P/E Ratio
1.62% Div Yield
660,062 Volume
3.83 Eps
$ 57.58
Previous Close
Add Transaction
Day Range
56.3 57.98
Year Range
46.3 65.65
Want to track ASH and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
ASH's Agrimer Eco-Coat Gets EPA Approval for Pesticide Use in the US

ASH's Agrimer Eco-Coat Gets EPA Approval for Pesticide Use in the US

Ashland's agrimer eco-coat polymer seed coating wins U.S. EPA approval, expanding market access and enabling use across food and non-food pesticide formulations.

Zacks | 3 months ago
Ashland Inc. (ASH) Q1 2026 Earnings Call Transcript

Ashland Inc. (ASH) Q1 2026 Earnings Call Transcript

Ashland Inc. (ASH) Q1 2026 Earnings Call Transcript

Seekingalpha | 4 months ago
ASH Q1 Earnings Beat, Sales Miss on Avoca Divestiture, Weak Demand

ASH Q1 Earnings Beat, Sales Miss on Avoca Divestiture, Weak Demand

Ashland Q1 2026 loss narrowed y/y and its earnings topped estimates. Sales fell 5% as divestitures and softer end-market demand weighed on results.

Zacks | 4 months ago
Ashland (ASH) Reports Q1 Earnings: What Key Metrics Have to Say

Ashland (ASH) Reports Q1 Earnings: What Key Metrics Have to Say

Although the revenue and EPS for Ashland (ASH) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks | 4 months ago
Ashland (ASH) Beats Q1 Earnings Estimates

Ashland (ASH) Beats Q1 Earnings Estimates

Ashland (ASH) came out with quarterly earnings of $0.26 per share, beating the Zacks Consensus Estimate of $0.23 per share. This compares to earnings of $0.28 per share a year ago.

Zacks | 4 months ago
Lyell Immunopharma: LYL314 Drives Momentum Amid Strong ASH Data

Lyell Immunopharma: LYL314 Drives Momentum Amid Strong ASH Data

Lyell Immunopharma (LYEL) has surged 191% YTD, driven by strong momentum and promising CAR T-cell therapy pipeline candidates LYL314 and LYL273. LYL314 achieved a 93% overall response and 76% complete response rate in heavily pre-treated LBCL, positioning LYEL as a differentiated player in CAR T therapies. LYEL maintains a $320 million cash position, funding operations into 2027, with pivotal LYL314 trial data and a BLA submission targeted for 2027.

Seekingalpha | 5 months ago
Ashland (ASH) Up 14.9% Since Last Earnings Report: Can It Continue?

Ashland (ASH) Up 14.9% Since Last Earnings Report: Can It Continue?

Ashland (ASH) reported earnings 30 days ago. What's next for the stock?

Zacks | 6 months ago
Ashland Q4 Earnings Miss Estimates on Portfolio Actions, Revenues Down

Ashland Q4 Earnings Miss Estimates on Portfolio Actions, Revenues Down

ASH posts higher Q4 profit but weaker adjusted earnings as sales fall across key segments amid portfolio shifts.

Zacks | 6 months ago
Ashland (ASH) Reports Q4 Earnings: What Key Metrics Have to Say

Ashland (ASH) Reports Q4 Earnings: What Key Metrics Have to Say

While the top- and bottom-line numbers for Ashland (ASH) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zacks | 7 months ago
Ashland (ASH) Q4 Earnings Lag Estimates

Ashland (ASH) Q4 Earnings Lag Estimates

Ashland (ASH) came out with quarterly earnings of $1.08 per share, missing the Zacks Consensus Estimate of $1.17 per share. This compares to earnings of $1.26 per share a year ago.

Zacks | 7 months ago
Analysts Estimate Ashland (ASH) to Report a Decline in Earnings: What to Look Out for

Analysts Estimate Ashland (ASH) to Report a Decline in Earnings: What to Look Out for

Ashland (ASH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks | 7 months ago
Is the Options Market Predicting a Spike in Ashland Stock?

Is the Options Market Predicting a Spike in Ashland Stock?

Investors need to pay close attention to ASH stock based on the movements in the options market lately.

Zacks | 9 months ago
Loading...
Load More